Catalyst overview
Research summary
This catalyst tracks a Phase 1b data readout for XEN901/NBI-921352 in Epilepsy, Focal Onset Seizures. The expected timing is based on the latest available company guidance and may change.
Partnered w/ Neurocrine. 9/14/23- Completed patient enrollment. 11/9/23- Ph2 proof-of-concept study failed to demonstrate meaningful reduction in seizure frequency. 11/03/25:- PR No update. 02/26/26:- Partnered NBI-921355 Phase 1 epilepsy study ongoing; selective NaV1.2/NaV1.6 inhibitor; no new timelines disclosed. 05/07/26:- NBI-921355 Phase 1b epilepsy study ongoing; data readout expected in 2027. 08/06/26:- NBI-921355 Phase 1b epilepsy data remains expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.